Health Condition 1: R730- Abnormal glucose
Conditions
Interventions
Intervention1: Millet (Sorghum), 250 grams/day for 6 months: Millet sorghum (Jawari flour) 250 gram per day for 6 months.
The sorghum (jawari flour) can be consumed in the form of Indian bread (bhaka
it will have a white-coloured body capsule
The participants will be given a bottle of 60 capsules once a month.
The participants will take 1 oral capsule (500 mg) before breakfast daily for 6 months.
Sponsors
Central Research and Publication Unit
Eligibility
Inclusion criteria
Inclusion criteria: For Millets intervention-Patients who can eat sorghum daily For cinnamon intervention- Patients who can ready to consume Cinnamon daily for 6 months
Exclusion criteria
Exclusion criteria: Known Diabetic patients Patients with a history of an allergy to cinnamon and sorghum Patients who are eating Sorghum and cinnamon daily Taking medications affecting glucose tolerance (glucocorticoids, anti-psychotic drugs and anti-retroviral drugs).) Daily alcohol consumption Patients with diagnosed alcoholic liver disease (ALD), cirrhosis Patients with renal failure Patients with symptoms suggestive of peptic ulcer disease and those with a past history of peptic ulceration Patients with cardiac, liver, or respiratory failure Patients with bleeding disorders and who are taking coumarin derivatives (e.g., warfarin) Patients with any malignancy Pregnancy and Lactation Patient who is planning for pregnancy in the study period Any condition that, in the opinion of the primary investigator, would contraindicate the patient s participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBA1c (Glycosylated Hemoglobin)Timepoint: At Baseline (Start of study) At 3 months (Mid of study) and At 6 months (End of study) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Cardiovascular disease risk- which includes Anthropometric parameters such as height, body weight, waist & hip circumferences, systolic & diastolic blood pressure readings, Biochemical measurements like Total cholesterol (mg/dL) Triglycerides (mg/dL) High-density lipoprotein (mg/dL) Low-density lipoprotein (mg/dL) 2. Obstructive sleep apnoea-The Berlin Questionnaire will be used to assess each participant s Obstructive Sleep Apnea risk status 3. Sleep Quality- Sleep quality will be assessed by using Pittsburgh Sleep Quality Index (PSQI), a validated questionnaire for the assessment of sleep patterns & their predictors Timepoint: At Baseline (Start of the study) & At 6 months (End of the study) | — |
Countries
India
Contacts
Public ContactDr Sudhanshu Ashok Mahajan
Professor and Head of Central Research and Publication Unit
Outcome results
None listed